Revenue surges by 42% and returns to profitability! Artificial disc leader Centinel Spine races for US IPO as innovative medical devices face valuation test

According to Zhitong Finance APP, leading U.S. medical device manufacturer Centinel Spine disclosed in its IPO filing submitted to the U.S. stock market on Wednesday local time that its revenue grew by a significant 42% in the first half of the year. Centinel Spine's IPO application provides global investors focused on the medical device sector with a reference case of “simultaneous acceleration in technology commercialization, revenue growth, and profitability improvement.”

For the global medical device sector, the investment significance of Centinel Spine's IPO mainly lies in the fact that specialized companies with clear clinical applications, sustained commercialization capability, and a profit base have the opportunity to achieve differentiated pricing. Ultimately, the IPO offering, valuation calculation, and market subscription performance will test how high a premium the market is willing to pay for this innovation-led growth quality in the medical device industry. As of now, the company has not completed its IPO or finalized its valuation pricing.

It is understood that this IPO filing comes at a time when the outlook for the global IPO market in the fall is uncertain. The surge in long-term U.S. Treasury yields (10 years or more), leading to rising global bond yields, and continued high interest rates as central banks fight inflation have dampened investor enthusiasm and prompted several major companies—including OpenAI and Anthropic—to postpone their listings.

Before the IPO: 42% Revenue Growth and Strong Reversal from Losses

This medical device company, headquartered in West Chester, Pennsylvania, achieved approximately $85.2 million in revenue and around $10.2 million in net profit in the six months ended June 30; in contrast, the same period last year saw $60.1 million in revenue and a net loss of about $503,000.

Centinel Spine researches and manufactures artificial discs designed to preserve mobility in the cervical and lumbar spine, offering an alternative to spinal fusion surgery. Spinal fusion typically permanently eliminates movement at the treated segments.

Fusion is achieved by inserting bone grafts, often with screws and rods for fixation, allowing adjacent vertebrae to eventually fuse into a solid bony mass. Once fusion is successful, the relative motion between the two vertebrae disappears, while the remaining unfused segments retain their mobility.

Why can this sometimes improve function? Because some diseased segments are in a state where “any movement is painful and structurally unstable.” By sacrificing mobility in these segments, fusion reduces painful motion and restores stability; when there is nerve compression, decompression may be performed simultaneously. While patients experience some loss of local flexibility, reduced pain may actually make it easier for them to stand, walk, and perform daily activities. The extent of impact depends on the location, range of the fusion, and the underlying condition—results vary among patients. In contrast, artificial disc technology aims to replace the diseased disc with a movable implant that preserves motion in the affected segment, while relieving symptoms. However, preserving motion does not mean artificial discs are suitable for every patient.

According to the company, its prodisc platform has been used in more than 300,000 implantations globally, supported by over 590 peer-reviewed clinical publications.

IPOX research assistant Lukas Muehlbauer told the media, “A notable point in Centinel’s filing is that the company can maintain strong profitability along with robust revenue growth, distinguishing itself from many healthcare companies preparing to go public.”

“Meanwhile, the company’s focus on total disc replacement creates a high degree of business concentration risk, exposing it to policy changes in reimbursement and the impact of competing technologies.”

Centinel Spine plans to use the proceeds from this offering to repay debt and invest in sales infrastructure, patient education initiatives, and clinical trials.

It is understood that investment banks such as Morgan Stanley, Goldman Sachs, Piper Sandler, Canaccord Genuity, and BTIG are underwriting the deal. The company plans to list on the New York Stock Exchange with the proposed ticker symbol “CNTL.”

On October 7, the company disclosed that revenue for the first half of 2026 increased from $60.1 million to $85.2 million, a year-on-year increase of about 42%; net profit reached $10.2 million, compared to a loss of $503,000 in the same period last year—implying a net margin increase from around -0.8% to 12.0%. The company intends to list under the ticker “CNTL” on the NYSE, raising funds for debt repayment, sales system construction, patient education, and clinical trials. Against the backdrop of high interest rates and rising bond yields suppressing global stock market valuations and IPO demand, this combination is more likely to focus investors on the company’s current revenue and profit as measures of commercial value.

How the Artificial Disc Leader Converts Technical Barriers into Profitability

Centinel Spine is a U.S.-based medical device company headquartered in West Chester, Pennsylvania, specializing in Total Disc Replacement (TDR). Its core prodisc platform covers cervical and lumbar artificial discs, designed to replace diseased discs while preserving mobility in the treated segments, thus offering an alternative to spinal fusion for appropriately indicated patients.

After divesting its fusion business in 2023, the company further focused on this field. According to company statistics, the prodisc series has been implanted more than 300,000 times worldwide, with over 590 related publications. Its business competitiveness is built on advanced implant design, long-term clinical evidence, approved indications, and a stronger and expanding network of physicians and sales channels.

The company’s recent strong growth is fundamentally driven by the expansion of indications, increased physician adoption, and broader sales coverage—jointly boosting product penetration. The FDA approved prodisc C Vivo and C SK for one or two contiguous cervical segments in October 2025, laying the foundation for further commercial expansion. However, the company’s focus on a single technology path, while providing specialized advantages, means that reimbursement policy changes and substitute technologies will have a more direct impact on its valuation.

From an investment research perspective, expansion in the applicable patient population, increased physician experience, and extension of the sales network may all drive growth in implant revenues. If incremental revenue can cover corresponding sales, R&D, and clinical inputs, economies of scale could be formed. The simultaneous appearance of revenue growth and profitability improvement is a noteworthy sign, but the company’s disclosed news is insufficient to attribute all profit improvement to operational leverage, nor can the 42% growth be fully attributed to any single product approval. For global peers in the medical device sector, the more comparable indicators are growth in surgery and implant volumes, product penetration rate, payer coverage, and sustainable profitability.

In terms of valuation, there is currently no confirmed IPO equity valuation. As of now, publicly available information shows the company has not disclosed its price range or share count; the approximately $100 million listed by IPO tracking agencies is the intended fundraising amount, not the company’s valuation, and the final offer size is yet to be determined. The company’s future valuation impact on the medical device sector mainly lies in providing a new valuation reference for “high growth and already profitable” specialized medical device enterprises; this benchmark is more direct for artificial disc and similar orthopedic innovative device companies.